Navigation Links
InformationWeek Puts Roche Diagnostics on Top 500 Innovative Tech Users List
Date:10/7/2008

Roche Diagnostics Makes List for Fourth Consecutive Year

INDIANAPOLIS, Oct. 7 /PRNewswire/ -- InformationWeek ranked Roche Diagnostics as one of the magazine's Top 500 innovative users of technology, an honor bestowed to only a handful of companies in the biotech and pharmaceutical industry.

Roche Diagnostics, which ranked No. 86, in the 2008 report, outperformed others in business-process efficiencies through increased automation, improved data integration, re-engineered applications and centralized control of IT operations.

"This is a great honor to be recognized by InformationWeek as being 86th out of the Top 500 Innovators and a great achievement for the Roche Diagnostics' North America IT team. They have implemented key business- technology strategies that InformationWeek considers to show bottom line efficiency and innovation," said Kurt Seiler, Vice President of Information Technology at Roche Diagnostics North America."

For nearly 20 years, InformationWeek 500 has tracked and listed technology practices of the nation's most innovative companies, including evaluation of technology deployment, IT budgets, business-technology infrastructure and IT strategies.

InformationWeek 500 is unique among corporate rankings, as it spotlights the power of innovation in information technology by measuring and celebrating accomplishments, rather than simply identifying the biggest IT spenders. To be eligible for ranking on this year's list, Roche Diagnostics' North American information technology department was assessed on best IT and Business practices across core areas of operations, including IT budgets, technology deployment, strategies, and staffing.

About Roche and the Roche Diagnostics Division

Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As a supplier of innovative products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people's health and quality of life. Roche is a world leader in diagnostics, the leading supplier of drugs for cancer and transplantation and a market leader in virology. In 2006, sales by the Pharmaceuticals Division totaled 33.3 billion Swiss francs, and the Diagnostics Division posted sales of 8.7 billion Swiss francs. Roche employs roughly 75,000 people in 150 countries and has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai. Roche's Diagnostics Division offers a uniquely broad product portfolio and supplies a wide array of innovative testing products and services to researchers, physicians, patients, hospitals and laboratories world-wide. For further information, please visit our U.S. Web site at http://www.roche-diagnostics.us .

All trademarks used or mentioned in this release are legally protected by law.

For further information please contact:

Julie Vincent

Corporate Communications

Roche Diagnostics Corporation

Indianapolis, IN.

Phone: 317-521-1910

julie.vincent@roche.com


'/>"/>
SOURCE Roche Diagnostics
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Exiqon A/S Today Announces a Grant of License to Roche Diagnostics
2. Roche completes acquisition of ARIUS
3. Affitech Announces Second Milestone in Roche Antibody Discovery Collaboration
4. Arius announces leading independent proxy firm, RiskMetrics ISS Canada, recommends shareholders vote for the arrangement involving its acquisition by Roche
5. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
6. Roche and Response Biomedical Corporation Aim to Reduce Vein-to-Brain Time with New Point-of-Care Cardiac Tests
7. Rochester Medical Announces Third Quarter 2008 Earnings Conference Call July 31, 2008
8. Roche starts acquisition process of ARIUS to gain access to new screening platform for antibody therapeutics
9. Roche Proposes to buy Full Stake in Genentech - Interview With Chairman
10. Roche Makes Offer to Acquire All Outstanding Shares of Genentech for US$89.00 Per Share in Cash
11. Access Pharmaceuticals Signs Merger Agreement to Acquire MacroChem Corp.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... ... September 20, 2017 , ... ... of a study examining the effects of exoskeleton-assisted walking on gait parameters ... (SCI). The article, "Neuromechanical adaptations during a robotic powered exoskeleton assisted walking ...
(Date:9/20/2017)... ... September 20, 2017 , ... RoviSys, a leading ... today the opening of an office in Taipei, Taiwan. This new location allows ... while developing new relationships in the region. Located in the Neihu area of ...
(Date:9/19/2017)... Philadelphia, PA (PRWEB) , ... September 19, 2017 ... ... are joining Philadelphia’s largest group of funded early-stage tech companies. “Grit” author Angela ... anchor tenant. Also joining the ic@3401 community is Cooley, an international law firm ...
(Date:9/19/2017)... ... September 19, 2017 , ... One of the biggest ... eliminated, said Lyle Probst, President, CEO and Founder of ExcitePCR ™. ... pathogen detection solutions, Probst said, “Sample preparation takes place inside our FireflyDX systems, ...
Breaking Biology Technology:
(Date:4/13/2017)... April 13, 2017 According to a new market ... Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, ... Market is expected to grow from USD 14.30 Billion in 2017 to ... of 17.3%. ... MarketsandMarkets Logo ...
(Date:4/6/2017)... Forecasts by Product Type (EAC), ... End-Use (Transportation & Logistics, Government & Public Sector, Utilities ... Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), ... you looking for a definitive report on the $27.9bn ... ...
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
Breaking Biology News(10 mins):